Immunology superstar Dupixent, which first brought Regeneron and Sanofi together in 2007, has entered its megablockbuster era. But even as the billions pile up, Regeneron isn't entirely happy with ...

Your trusted source for the latest news delivered weekdays from the team at U.S. News and World Report. Sign in to manage your newsletters » Sign up to receive the latest updates from U.S News ...

A free daily email with the biggest news stories of the day – and the best features from TheWeek.com Contact me with news and offers from other Future brands Receive email from us on behalf of ...

A free daily email with the biggest news stories of the day – and the best features from TheWeek.com Contact me with news and offers from other Future brands Receive email from us on behalf of ...

Cartoon Nick Kyrgios winces in pain at real Nick Kyrgios’ injured abdominal during his first round loss to Brit jacob fearnley (Image: Australian Open Animated) The animated feed includes the ...

Bristol Myers Squibb has continued its ruthless cost-cutting push, dropping plans to commercialize a rival to Dupixent despite meeting its phase 3 goals and pumping the brakes on a would-be ...

Despite Eylea's market challenges, Dupixent's strong performance and future potential in COPD, along with a robust pipeline, position Regeneron for recovery in 2025. Regeneron's solid financials ...

One primary reason is the strong performance and potential of Dupixent, which is expected to partially counterbalance the uncertainties surrounding Eylea. The expected growth in Dupixent’s ...

Add galleries to your saved list and come back to them any time.

The CEO discussed the success of Dupixent and the remarkable achievement of over $13 billion in global sales in 2024, highlighting its commercial advantage and setting a milestone for Sanofi.

Sanofi and Regeneron have celebrated a pair of positive clinical trials in inflammatory skin disorders with blockbuster immunology therapy Dupixent that could both lead to new indications for the ...

Among other topics, Hudson discussed the success of Dupixent (dupilumab), highlighting that it has reached over $13bn in global sales, which affirms its commercial advantage and sets a milestone ...